Valentin Mocanu

Valentin Mocanu

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 September 2019 in Nutrients
Verified
Journal Article
Open access
PDF file
ZZZhengxiao Zhang
Zhengxiao Zhang
VMValentin Mocanu
Valentin Mocanu
CCChenxi Cai
Chenxi Cai
Jerry DangJerry Dang
Jerry Dang
LSLinda Slater
Linda Slater
KMKAREN MADSEN
KAREN MADSEN
Fecal microbiota transplantation (FMT) is a gut microbial-modulation strategy that has been investigated for the treatment of a variety of human diseases, including obesity-associated metabolic disorders. This study appraises current literature and provides an overview of the effectiveness and limitations of FMT as a potential therapeutic strategy for obesity and metabolic syndrome (MS). Five electronic databases and two gray literature sources were searched up to 10 December 2018. All interventional and observational studies that contained information on the relevant population (adult patients with obesity and MS), intervention (receiving allogeneic FMT) and outcomes (metabolic parameters) were eligible. From 1096 unique citations, three randomized placebo-controlled studies (76 patients with obesity and MS, body mass index = 34.8 ± 4.1 kg/m2, fasting plasma glucose = 5.8 ± 0.7 mmol/L) were included for review. Studies reported mixed results with regards to improvement in metabolic parameters. Two studies reported improved peripheral insulin sensitivity (rate of glucose disappearance, RD) at 6 weeks in patients receiving donor FMT versus patients receiving the placebo control. In addition, one study observed lower HbA1c levels in FMT patients at 6 weeks. No differences in fasting plasma glucose, hepatic insulin sensitivity, body mass index (BMI), or cholesterol markers were observed between two groups across all included studies. While promising, the influence of FMT on long-term clinical endpoints needs to be further explored. Future studies are also required to better understand the mechanisms through which changes in gut microbial ecology and engraftment of microbiota affect metabolic outcomes for patients with obesity and MS. In addition, further research is needed to better define the optimal fecal microbial preparation, dosing, and method of delivery.

1 May 2019 in The American Journal of Surgery
Verified
Journal Article
Closed access
VMValentin Mocanu
Valentin Mocanu
Jerry DangJerry Dang
Jerry Dang
FLFarah Ladak
Farah Ladak
CTChunhong Tian
Chunhong Tian
HWHaili Wang
Haili Wang
SKShahzeer Karmali
Shahzeer Karmali

15 March 2023 in Obesity Surgery
Verified
Journal Article
Closed access
PDF file
Jerry DangJerry Dang
Jerry Dang
TVTiffany Vaughan
Tiffany Vaughan
VMValentin Mocanu
Valentin Mocanu
HMHadika Mubashir
Hadika Mubashir
JBJuan S Barajas-Gamboa
Juan S Barajas-Gamboa
MKMatthew Kroh
Matthew Kroh

Verified
Journal Article
Open access
PDF file
VMValentin Mocanu
Valentin Mocanu
SRSabitha Rajaruban
Sabitha Rajaruban
Jerry DangJerry Dang
Jerry Dang
JKJanice Kung
Janice Kung
Edward C. DeehanEdward C. Deehan
Edward C. Deehan
KMKAREN MADSEN
KAREN MADSEN
The response of patients with inflammatory bowel disease (IBD) to fecal microbial transplantation (FMT) has been inconsistent possibly due to variable engraftment of donor microbiota. This failure to engraft has resulted in the use of several different strategies to attempt optimization of the recipient microbiota following FMT. The purpose of our study was to evaluate the effects of two distinct microbial strategies—antibiotic pre-treatment and repeated FMT dosing—on IBD outcomes. A systematic literature review was designed and implemented in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A medical librarian conducted comprehensive searches in MEDLINE, Embase, Scopus, Web of Science Core Collection, and Cochrane Library on 25 November 2019 and updated on 29 January 2021. Primary outcomes of interest included comparing relapse and remission rates in patients with IBD for a single FMT dose, repeated FMT dosages, and antibiotic pre-treatment groups. Twenty-eight articles (six randomized trials, 20 cohort trials, two case series) containing 976 patients were identified. Meta-analysis revealed that both repeated FMT and antibiotic pre-treatment strategies demonstrated improvements in pooled response and remission rates. These clinical improvements were associated with increases in fecal microbiota richness and α-diversity, as well as the enrichment of several short-chain fatty acid (SCFA)-producing anaerobes including Bifidobacterium, Roseburia, Lachnospiraceae, Prevotella, Ruminococcus, and Clostridium related species.

1 October 2019 in Surgery for Obesity and Related Diseases
Verified
Journal Article
Closed access
VMValentin Mocanu
Valentin Mocanu
Jerry DangJerry Dang
Jerry Dang
FLFarah Ladak
Farah Ladak
NSNoah Switzer
Noah Switzer
DBDaniel W. Birch
Daniel W. Birch
SKShahzeer Karmali
Shahzeer Karmali

29 April 2024 in Gut Microbes
Verified
Journal Article
Open access
ZZZhengxiao Zhang
Zhengxiao Zhang
VMValentin Mocanu
Valentin Mocanu
Edward C. DeehanEdward C. Deehan
Edward C. Deehan
NHNaomi Hotte
Naomi Hotte
YZYuanyuan Zhu
Yuanyuan Zhu
KMKAREN MADSEN
KAREN MADSEN
Obesity is a complex chronic progressive condition characterized by excess adiposity and dysregulation in enteroendocrine and neurohormonal signaling pathways favoring increased appetite and energy...